A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Phase: Phase III clinical trials
Principal Investigator: Dott.ssa Verzoni Elena
Main Facility: Oncologia Medica Genitourinaria
Drug: Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients
Pathologies: Urological cancers (kidney, bladder, urinary tract, others)
This is a Phase 3, randomized, active-control, placebo-controlled, double-blind, 2-arm, global, multicenter study to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib in adult patients with confirmed advanced or metastatic ccRCC who have experienced progression on or after prior anti-PD-1 or antiPD-L1 immunotherapy
Last update: 09/06/2026